Cargando…

Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series

BACKGROUND: In acute liver failure (ALF) therapeutic plasma exchange (TPE) improves laboratory measures of liver function. In patients with ALF requiring minimal vasoactive support TPE has also been shown to provide haemodynamic benefits including an increase in systemic blood pressure. However the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiersema, Ubbo F, Kim, Susan W, Roxby, David, Holt, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359494/
https://www.ncbi.nlm.nih.gov/pubmed/25774091
http://dx.doi.org/10.1186/s12871-015-0017-9
_version_ 1782361417285894144
author Wiersema, Ubbo F
Kim, Susan W
Roxby, David
Holt, Andrew
author_facet Wiersema, Ubbo F
Kim, Susan W
Roxby, David
Holt, Andrew
author_sort Wiersema, Ubbo F
collection PubMed
description BACKGROUND: In acute liver failure (ALF) therapeutic plasma exchange (TPE) improves laboratory measures of liver function. In patients with ALF requiring minimal vasoactive support TPE has also been shown to provide haemodynamic benefits including an increase in systemic blood pressure. However the haemodynamic effects of TPE in patients with severe ALF requiring moderate or high dose vasopressor therapy has not been reported. We retrospectively examined the haemodynamic effects of TPE in a cohort of patients with severe ALF requiring vasopressor therapy. METHODS: Physiological, laboratory and treatment data were collected on all patients with ALF who received TPE between January 2000 and December 2012. All patients were managed in the intensive care unit of a tertiary referral centre for ALF and liver transplantation. The primary outcome measures were changes in mean arterial pressure (MAP), vasopressor score and the ratio of vasopressor score to MAP (vasopressor dependency index (VDI)) from baseline prior to TPE through to 12 hours after completion of TPE. Secondary outcome measures were changes in other routinely collected physiological variables and laboratory results. Results are presented as median (interquartile range (IQR)). Outcome measures were evaluated using a mixed effect model. RESULTS: Thirty nine TPE were performed in 17 patients with ALF (13 paracetamol poisoning). All TPE were performed with a centrifugal apheresis system (duration 130 minutes (IQR 115 – 147.5), plasma volume removed 5.1% body weight (IQR 4.6 – 5.5). Baseline values for primary outcome measures were: MAP 82 mmHg (IQR 72 – 92.5), vasopressor score 8.35 (IQR 3.62 – 24.6) and VDI 0.10 (IQR 0.05 – 0.31). MAP was significantly higher immediately after TPE compared to baseline (p = 0.039), however when corrected for change in vasopressor requirement there was no significant change in VDI with TPE (p = 0.953). Twelve hours after TPE the MAP, vasopressor score and VDI were not significantly different from baseline (p = 0.563, p = 0.317 and p = 0.214 respectively). CONCLUSION: In this cohort of patients with severe ALF centrifugal TPE did not significantly affect vasopressor requirements. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12871-015-0017-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4359494
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43594942015-03-15 Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series Wiersema, Ubbo F Kim, Susan W Roxby, David Holt, Andrew BMC Anesthesiol Research Article BACKGROUND: In acute liver failure (ALF) therapeutic plasma exchange (TPE) improves laboratory measures of liver function. In patients with ALF requiring minimal vasoactive support TPE has also been shown to provide haemodynamic benefits including an increase in systemic blood pressure. However the haemodynamic effects of TPE in patients with severe ALF requiring moderate or high dose vasopressor therapy has not been reported. We retrospectively examined the haemodynamic effects of TPE in a cohort of patients with severe ALF requiring vasopressor therapy. METHODS: Physiological, laboratory and treatment data were collected on all patients with ALF who received TPE between January 2000 and December 2012. All patients were managed in the intensive care unit of a tertiary referral centre for ALF and liver transplantation. The primary outcome measures were changes in mean arterial pressure (MAP), vasopressor score and the ratio of vasopressor score to MAP (vasopressor dependency index (VDI)) from baseline prior to TPE through to 12 hours after completion of TPE. Secondary outcome measures were changes in other routinely collected physiological variables and laboratory results. Results are presented as median (interquartile range (IQR)). Outcome measures were evaluated using a mixed effect model. RESULTS: Thirty nine TPE were performed in 17 patients with ALF (13 paracetamol poisoning). All TPE were performed with a centrifugal apheresis system (duration 130 minutes (IQR 115 – 147.5), plasma volume removed 5.1% body weight (IQR 4.6 – 5.5). Baseline values for primary outcome measures were: MAP 82 mmHg (IQR 72 – 92.5), vasopressor score 8.35 (IQR 3.62 – 24.6) and VDI 0.10 (IQR 0.05 – 0.31). MAP was significantly higher immediately after TPE compared to baseline (p = 0.039), however when corrected for change in vasopressor requirement there was no significant change in VDI with TPE (p = 0.953). Twelve hours after TPE the MAP, vasopressor score and VDI were not significantly different from baseline (p = 0.563, p = 0.317 and p = 0.214 respectively). CONCLUSION: In this cohort of patients with severe ALF centrifugal TPE did not significantly affect vasopressor requirements. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12871-015-0017-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-08 /pmc/articles/PMC4359494/ /pubmed/25774091 http://dx.doi.org/10.1186/s12871-015-0017-9 Text en © Wiersema et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wiersema, Ubbo F
Kim, Susan W
Roxby, David
Holt, Andrew
Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title_full Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title_fullStr Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title_full_unstemmed Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title_short Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
title_sort therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359494/
https://www.ncbi.nlm.nih.gov/pubmed/25774091
http://dx.doi.org/10.1186/s12871-015-0017-9
work_keys_str_mv AT wiersemaubbof therapeuticplasmaexchangedoesnotreducevasopressorrequirementinsevereacuteliverfailurearetrospectivecaseseries
AT kimsusanw therapeuticplasmaexchangedoesnotreducevasopressorrequirementinsevereacuteliverfailurearetrospectivecaseseries
AT roxbydavid therapeuticplasmaexchangedoesnotreducevasopressorrequirementinsevereacuteliverfailurearetrospectivecaseseries
AT holtandrew therapeuticplasmaexchangedoesnotreducevasopressorrequirementinsevereacuteliverfailurearetrospectivecaseseries